CDK4 anticorps (AA 150-303)

N° du produit ABIN7870918

Cet anticorps anti-CDK4 Monoclonal Souris (Clone CDK4-8896) (ABIN7870918) détecte spécifiquement CDK4 dans IHC (p). L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour CDK4 anticorps (AA 150-303) (ABIN7870918)

Antigène: CDK4 (Cyclin-Dependent Kinase 4 (CDK4))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CDK4 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Classe de qualité: Carrier-free

Clone: CDK4-8896

Détail du produit anti-CDK4 anticorps

Épitope: AA 150-303

Fonction: Cyclin-dependent kinase 4 Antibody / CDK4 (azide and preservative free)

Purification: Protein A/G affinity

Immunogène: A recombinant fragment (within amino acids 150-303) of human Cyclin-dependent kinase 4 protein was used as the immunogen for the Cyclin-dependent kinase 4 antibody.

Isotype: IgG1, kappa

Information d'application

Indications d'application: Optimal dilution of the Cyclin-dependent kinase 4 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Aliquot the Cyclin-dependent kinase 4 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur CDK4

Antigène: CDK4 (Cyclin-Dependent Kinase 4 (CDK4))

Autre désignation: Cyclin-dependent kinase 4

Sujet: Cyclin-dependent kinase-4 (CDK4) is a protein-serine kinase involved in the cell cycle. It is essential for the G1- to S-phase transition during the cell cycle and its expression is primarily controlled at the transcriptional level (PMID:17253961). CCND1- CDK4 axis is not only critical in glial tumor cells but also in stromal-derived cells in the surrounding tumor microenvironment that are vital to sustain tumor outgrowth (PMID:21844184). CDK4 is highly expressed in highly differentiated and dedifferentiated liposarcomas, but rarely expressed in other benign liposarcomas and other sarcomas. CDK4 and MDM2 combined to differentiate between highly differentiated liposarcoma (+), dedifferentiated liposarcoma (+) and myxoid liposarcoma, pleomorphic liposarcoma, spindle lipoma, pleomorphic lipoma and other high-grade sarcomas.

UniProt: P11802

Pathways: Cycle Cellulaire, Mitotic G1-G1/S Phases, Regulation of Cell Size